Press Releases

INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights

Posted on March 1, 2023

INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Posted on February 16, 2023

INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023

Posted on February 15, 2023

INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)

Posted on February 2, 2023

INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates

Posted on January 31, 2023

INOVIO Provides an Update on Lassa Fever and MERS Programs

Posted on November 17, 2022

INOVIO Reports Financial Results and Highlights for the Third Quarter 2022

Posted on November 8, 2022

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

Posted on October 27, 2022

INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022

Posted on October 25, 2022

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Posted on October 13, 2022

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.